• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
  • About Us
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Poster: Prospectively Assessing the Immunogenic Risk of Potential Synthetic Peptide Impurities in silico with the What-if Machine (WhIM)

Poster: Prospectively Assessing the Immunogenic Risk of Potential Synthetic Peptide Impurities in silico with the What-if Machine (WhIM)

by Elena Iemma | Sep 21, 2023

Prospectively Assessing the Immunogenic Risk of Potential Synthetic Peptide Impurities in silico with the What-if Machine (WhIM)
Immunoinformatic Risk Assessment of Host Cell Proteins During Process Development for Biologic Therapeutics

Immunoinformatic Risk Assessment of Host Cell Proteins During Process Development for Biologic Therapeutics

by Elena Iemma | Sep 12, 2023

Immunogenicity risk assessment of synthetic peptide drugs and their impurities

Immunogenicity risk assessment of synthetic peptide drugs and their impurities

by Elena Iemma | Jul 27, 2023

Immunogenicity risk assessment of synthetic peptide drugs and their impurities – ScienceDirect
Poster: Innovative preclinical assessment tools for safety and efficacy of protein and peptide therapeutics… Of Peptides and P-ANDAS

Poster: Innovative preclinical assessment tools for safety and efficacy of protein and peptide therapeutics… Of Peptides and P-ANDAS

by Elena Iemma | Sep 22, 2022

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics… of Peptides and P-ANDAS
Next Entries »

Recent Posts

  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy 
  • BEBPA Workshop: Streamlining Immunogenicity Assessment of Host Cell Proteins
  • Advancing Immunogenicity Science: EpiVax in 2025 
  • EpiVax Supports Life-Saving Programs Through Partnerships with GAIA Vaccine Foundation and Clínica Esperanza/Hope Clinic

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.